Ascendis Pharma A/s (ASND)

$95.06

-0.38

(-0.4%)▲

Market is closed - opens 7 PM, 25 Sep 2023

Insights on Ascendis Pharma A/s

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 33.58K → 47.39M (in $), with an average increase of 99.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -207.41M → -121.43M (in $), with an average increase of 70.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 294.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 451.5% return, outperforming this stock by 489.8%

Performance

  • $94.59
    $97.07
    $95.06
    downward going graph

    0.5%

    Downside

    Day's Volatility :2.56%

    Upside

    2.07%

    downward going graph
  • $64.33
    $134.53
    $95.06
    downward going graph

    32.33%

    Downside

    52 Weeks Volatility :52.18%

    Upside

    29.34%

    downward going graph

Returns

PeriodAscendis Pharma A/sSector (Health Care)Index (Russel 2000)
3 Months
9.77%
-1.4%
0.0%
6 Months
-12.44%
2.2%
2.0%
1 Year
-3.64%
6.0%
5.3%
3 Years
-38.28%
26.3%
19.9%

Highlights

Market Capitalization
5.4B
Book Value
$1.15
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-10.84
Wall Street Target Price
0.34
Profit Margin
0.0%
Operating Margin TTM
-483.7%
Return On Assets TTM
-33.5%
Return On Equity TTM
-180.98%
Revenue TTM
119.2M
Revenue Per Share TTM
2.13
Quarterly Revenue Growth YOY
669.4%
Gross Profit TTM
39.0M
EBITDA
-570.3M
Diluted Eps TTM
-10.84
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.04
EPS Estimate Next Year
-0.01
EPS Estimate Current Quarter
-2.74
EPS Estimate Next Quarter
-2.69

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Ascendis Pharma A/s(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
16
19
Hold
5
5
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 99.64%

Current $95.06
Target $0.34

Company Financials

FY17Y/Y Change
Revenue
1.5M
↓ 66.78%
Net Income
-123.9M
↑ 80.86%
Net Profit Margin
-8.1K%
↓ 6610.54%
FY18Y/Y Change
Revenue
10.6M
↑ 591.57%
Net Income
-130.1M
↑ 5.0%
Net Profit Margin
-1.2K%
↑ 6868.31%
FY19Y/Y Change
Revenue
13.4M
↑ 26.41%
Net Income
-218.0M
↑ 67.58%
Net Profit Margin
-1.6K%
↓ 400.5%
FY20Y/Y Change
Revenue
7.0M
↓ 48.01%
Net Income
-419.0M
↑ 92.17%
Net Profit Margin
-6.0K%
↓ 4395.5%
FY21Y/Y Change
Revenue
8.8M
↑ 11.87%
Net Income
-434.4M
↓ 8.44%
Net Profit Margin
-4.9K%
↑ 1093.97%
FY22Y/Y Change
Revenue
54.8M
↑ 557.93%
Net Income
-624.7M
↑ 52.04%
Net Profit Margin
-1.1K%
↑ 3791.93%
Q1 FY22Q/Q Change
Revenue
7.6M
↑ 39.4%
Net Income
-140.1M
↑ 18.32%
Net Profit Margin
-1.8K%
↑ 327.44%
Q2 FY22Q/Q Change
Revenue
6.4M
↓ 9.78%
Net Income
-85.0M
↓ 35.2%
Net Profit Margin
-1.3K%
↑ 517.88%
Q3 FY22Q/Q Change
Revenue
15.0M
↑ 148.21%
Net Income
-166.1M
↑ 107.77%
Net Profit Margin
-1.1K%
↑ 215.11%
Q4 FY22Q/Q Change
Revenue
24.5M
↑ 49.74%
Net Income
-222.2M
↑ 22.77%
Net Profit Margin
-905.91%
↑ 199.09%
Q2 FY23Q/Q Change
Revenue
51.7M
↑ 140996.79%
Net Income
-132.5M
-
Net Profit Margin
-256.23%
-
FY17Y/Y Change
Total Assets
211.0M
↑ 11.0%
Total Liabilities
23.8M
↑ 76.61%
FY18Y/Y Change
Total Assets
319.0M
↑ 51.18%
Total Liabilities
38.9M
↑ 63.74%
FY19Y/Y Change
Total Assets
676.7M
↑ 112.16%
Total Liabilities
79.6M
↑ 104.58%
FY20Y/Y Change
Total Assets
979.8M
↑ 44.78%
Total Liabilities
141.1M
↑ 77.2%
FY21Y/Y Change
Total Assets
1.2B
↑ 10.73%
Total Liabilities
228.0M
↑ 42.67%
FY22Y/Y Change
Total Assets
1.2B
↑ 0.44%
Total Liabilities
885.3M
↑ 310.56%
Q1 FY22Q/Q Change
Total Assets
1.5B
↑ 26.94%
Total Liabilities
786.3M
↑ 249.97%
Q2 FY22Q/Q Change
Total Assets
1.4B
↓ 3.66%
Total Liabilities
751.1M
↑ 2.07%
Q3 FY22Q/Q Change
Total Assets
1.3B
↓ 4.03%
Total Liabilities
807.9M
↑ 14.31%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 14.42%
Total Liabilities
885.3M
↑ 0.55%
Q1 FY23Q/Q Change
Total Assets
1.1B
↓ 11.33%
Total Liabilities
871.4M
↓ 3.31%
Q2 FY23Q/Q Change
Total Assets
898.9M
↓ 14.74%
Total Liabilities
828.1M
↓ 5.02%
FY17Y/Y Change
Operating Cash Flow
-95.1M
↑ 58.03%
Investing Cash Flow
-941.0K
↑ 40.03%
Financing Cash Flow
124.7M
↑ 6.18%
FY18Y/Y Change
Operating Cash Flow
-138.8M
↑ 45.96%
Investing Cash Flow
-2.6M
↑ 181.4%
Financing Cash Flow
203.3M
↑ 62.98%
FY19Y/Y Change
Operating Cash Flow
-175.9M
↑ 26.75%
Investing Cash Flow
-5.2M
↑ 94.83%
Financing Cash Flow
493.6M
↑ 142.83%
FY20Y/Y Change
Operating Cash Flow
-271.5M
↑ 54.34%
Investing Cash Flow
-291.2M
↑ 5544.49%
Financing Cash Flow
602.7M
↑ 22.09%
FY21Y/Y Change
Operating Cash Flow
-473.0M
↑ 53.8%
Investing Cash Flow
-125.2M
↓ 62.03%
Financing Cash Flow
397.9M
↓ 41.69%
Q1 FY22Q/Q Change
Operating Cash Flow
-146.0M
↑ 6.06%
Investing Cash Flow
43.0M
↓ 134.44%
Financing Cash Flow
444.0M
↓ 2028.04%
Q2 FY22Q/Q Change
Operating Cash Flow
-130.0M
↓ 4.89%
Investing Cash Flow
10.3M
↓ 74.34%
Financing Cash Flow
-2.3M
↓ 100.56%
Q3 FY22Q/Q Change
Operating Cash Flow
-97.2M
↓ 20.55%
Investing Cash Flow
13.9M
↑ 42.59%
Financing Cash Flow
-74.7K
↓ 96.6%

Technicals Summary

Sell

Neutral

Buy

Ascendis Pharma A/s is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ascendis Pharma A/s
Ascendis Pharma A/s
-3.89%
-12.44%
-3.64%
-38.28%
42.28%
Moderna, Inc.
Moderna, Inc.
-10.67%
-32.6%
-16.46%
43.93%
437.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.66%
0.54%
20.22%
43.69%
111.47%
Novo Nordisk A/s
Novo Nordisk A/s
2.15%
146.19%
299.73%
451.49%
690.33%
Seagen, Inc.
Seagen, Inc.
6.95%
7.06%
57.98%
15.54%
167.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.15%
13.31%
26.28%
30.33%
91.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ascendis Pharma A/s
Ascendis Pharma A/s
NA
NA
NA
-0.04
-1.81
-0.33
0.0
1.15
Moderna, Inc.
Moderna, Inc.
34.92
34.92
0.0
-3.42
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.9
21.9
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.86
42.86
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.48
27.48
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ascendis Pharma A/s
Ascendis Pharma A/s
Buy
$5.4B
42.28%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.1B
437.58%
34.92
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$89.4B
111.47%
21.9
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$409.3B
690.33%
42.86
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.7B
167.56%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
91.37%
27.48
35.4%

Institutional Holdings

  • RA Capital Management, LLC

    19.97%

  • Artisan Partners Limited Partnership

    11.07%

  • FMR Inc

    9.14%

  • T. Rowe Price Investment Management,Inc.

    7.08%

  • HHG PLC

    6.90%

  • Westfield Capital Management Company, LP

    6.46%

Corporate Announcements

  • Ascendis Pharma A/s Earnings

    Ascendis Pharma A/s’s price-to-earnings ratio stands at None

    Read More

Company Information

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.

Organization
Ascendis Pharma A/s
Employees
797
CEO
Mr. Jan Moller Mikkelsen
Industry
Health Technology

Discover More

FAQs